# BMB-101 in Absence Epilepsy and DEE

> **NCT06401538** · PHASE2 · RECRUITING · sponsor: **Bright Minds Biosciences Pty Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Absence Epilepsy
- Jeavons Syndrome
- Dravet Syndrome
- Lennox Gastaut Syndrome

## Interventions

- **DRUG:** BMB-101

## Key facts

- **NCT ID:** NCT06401538
- **Lead sponsor:** Bright Minds Biosciences Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401538, "BMB-101 in Absence Epilepsy and DEE". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06401538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*